Literature DB >> 26698867

p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.

Shunan Ye1,2, Jacson Shen1, Edwin Choy1, Cao Yang2, Henry Mankin1, Francis Hornicek1, Zhenfeng Duan3.   

Abstract

PURPOSE: Multidrug resistance (MDR) is a major obstacle to the successful treatment of osteosarcoma with chemotherapy. Effectiveness of cancer therapy correlates with the ability to induce a p53-dependent apoptotic response. p53 is a tumor suppressor gene that is mutated in 22 % of osteosarcomas. While impaired p53 has been implicated in the oncogenesis of osteosarcoma, it is unclear whether overexpression of wild-type p53 can increase chemosensitivity in MDR osteosarcoma cells.
METHODS: We transfected a plasmid encoding the wild-type p53 gene to MDR osteosarcoma cell lines, which have different p53 statuses, U-2OSR2 with wild-type p53 (Wt-p53) and KHOSR2 with mutant p53 (Mt-p53), and determined the effect of p53 overexpression on chemosensitivities.
RESULTS: Both of the U-2OSR2 and KHOSR2 cell lines displayed similar trends in p53-induced drug sensitivities. However, it seems that the impact of p53 overexpression is different based on the differential intrinsic p53 status in these cell lines. In the KHOSR2 cell line (Mt-p53), overexpression of p53 up-regulates the expression of pro-apoptotic protein p21 and Bax, while in the U-2OSR2 cell line (Wt-p53), overexpression of p53 down-regulates IGF-1r expression significantly.
CONCLUSIONS: These results demonstrated that transfection of wild-type p53 increases chemosensitivity either through inhibiting IGF-1r or through increasing the expression of pro-apoptotic proteins p21 and Bax in human MDR osteosarcoma cell lines.

Entities:  

Keywords:  Apoptosis; MDR; Osteosarcoma; p53

Mesh:

Substances:

Year:  2015        PMID: 26698867      PMCID: PMC4749432          DOI: 10.1007/s00280-015-2944-z

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  55 in total

1.  Mechanisms of resistance to apoptosis in human AML blasts: the role of differentiation-induced perturbations of cell-cycle checkpoints.

Authors:  N J Ketley; P D Allen; S M Kelsey; A C Newland
Journal:  Leukemia       Date:  2000-04       Impact factor: 11.528

2.  Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.

Authors:  J Sampath; D Sun; V J Kidd; J Grenet; A Gandhi; L H Shapiro; Q Wang; G P Zambetti; J D Schuetz
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

3.  An intact HDM2 RING-finger domain is required for nuclear exclusion of p53.

Authors:  S D Boyd; K Y Tsai; T Jacks
Journal:  Nat Cell Biol       Date:  2000-09       Impact factor: 28.824

Review 4.  Novel mechanisms of drug resistance in leukemia.

Authors:  D D Ross
Journal:  Leukemia       Date:  2000-03       Impact factor: 11.528

5.  Molecular determinants of treatment response in human germ cell tumors.

Authors:  Frank Mayer; Hans Stoop; George L Scheffer; Rik Scheper; J Wolter Oosterhuis; Leendert H J Looijenga; Carsten Bokemeyer
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

Review 6.  Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.

Authors:  R Z Yusuf; Z Duan; D E Lamendola; R T Penson; M V Seiden
Journal:  Curr Cancer Drug Targets       Date:  2003-02       Impact factor: 3.428

7.  Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line.

Authors:  Ze-Hong Miao; Lin-Jiang Tong; Jin-Sheng Zhang; Jia-Xian Han; Jian Ding
Journal:  Int J Cancer       Date:  2004-07-10       Impact factor: 7.396

Review 8.  Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy.

Authors:  Suxing Liu; W Robert Bishop; Ming Liu
Journal:  Drug Resist Updat       Date:  2003-08       Impact factor: 18.500

9.  Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.

Authors:  Douglas S Hawkins; Carola A S Arndt
Journal:  Cancer       Date:  2003-12-01       Impact factor: 6.860

10.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines.

Authors:  N Kartner; J R Riordan; V Ling
Journal:  Science       Date:  1983-09-23       Impact factor: 47.728

View more
  14 in total

1.  Synergistic effects of cisplatin-caffeic acid induces apoptosis in human cervical cancer cells via the mitochondrial pathways.

Authors:  Amonrat Koraneekit; Temduang Limpaiboon; Arunnee Sangka; Patcharee Boonsiri; Sakda Daduang; Jureerut Daduang
Journal:  Oncol Lett       Date:  2018-03-13       Impact factor: 2.967

Review 2.  Osteosarcoma: a review of current and future therapeutic approaches.

Authors:  Xin Zhao; Qirui Wu; Xiuqing Gong; Jinfeng Liu; Yujie Ma
Journal:  Biomed Eng Online       Date:  2021-03-02       Impact factor: 2.819

3.  Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.

Authors:  Chaojun Xue; Changyuan Wang; Yaoting Sun; Qiang Meng; Zhihao Liu; Xiaokui Huo; Pengyuan Sun; Huijun Sun; Xiaodong Ma; Xiaochi Ma; Jinyong Peng; Kexin Liu
Journal:  Oncotarget       Date:  2017-01-31

Review 4.  Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.

Authors:  Tang Liu; Zhihong Li; Qing Zhang; Karen De Amorim Bernstein; Santiago Lozano-Calderon; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Oncotarget       Date:  2016-12-13

Review 5.  Programming of Cell Resistance to Genotoxic and Oxidative Stress.

Authors:  Ilya O Velegzhaninov; Vitaly A Ievlev; Yana I Pylina; Dmitry M Shadrin; Olesya M Vakhrusheva
Journal:  Biomedicines       Date:  2018-01-02

6.  Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines.

Authors:  Michela Levi; Roberta Salaroli; Federico Parenti; Raffaella De Maria; Augusta Zannoni; Chiara Bernardini; Cecilia Gola; Antonio Brocco; Asia Marangio; Cinzia Benazzi; Luisa Vera Muscatello; Barbara Brunetti; Monica Forni; Giuseppe Sarli
Journal:  BMC Vet Res       Date:  2021-01-18       Impact factor: 2.741

7.  Verteporfin disrupts multiple steps of autophagy and regulates p53 to sensitize osteosarcoma cells.

Authors:  Heena Saini; Harshita Sharma; Sudeshna Mukherjee; Shibasish Chowdhury; Rajdeep Chowdhury
Journal:  Cancer Cell Int       Date:  2021-01-14       Impact factor: 5.722

8.  p53-Induced Autophagy Regulates Chemotherapy and Radiotherapy Resistance in Multidrug Resistance Cancer Cells.

Authors:  Shumei Ma; Dejuan Kong; Xinxin Fu; Lin Liu; Yi Liu; Chang Xue; Zhujun Tian; Lan Li; Xiaodong Liu
Journal:  Dose Response       Date:  2021-10-08       Impact factor: 2.658

9.  Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals.

Authors:  Pengjun Zhou; Rong Zhang; Ying Wang; Dandan Xu; Li Zhang; Jinhong Qin; Guifeng Su; Yue Feng; Hongce Chen; Siyuan You; Wen Rui; Huizhong Liu; Suhong Chen; Hongyuan Chen; Yifei Wang
Journal:  Oncotarget       Date:  2017-11-27

10.  Tetrandrine partially reverses multidrug resistance of human laryngeal cancer cells.

Authors:  Yachun Li; Dongjie Li; Ping Wang; Wei Zhu; Wanzhong Yin
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.